Sonoma Pharmaceuticals closes $3.5 million net public offering at $1.35 per share
Sonoma Pharmaceuticals sold shares, pre-funded warrants and warrants in a public offering priced at $1.35 per unit, with the offering closing on April 27 and 28, 2026, including full exercise of the underwriter's over-allotment option. The company expects net proceeds of about $3.5 million, and the filing also discloses warrants that could bring in additional cash, which adds potential share dilution for existing shareholders.
Key points
- Priced April 24, 2026 at $1.35 per unit; closed April 27 and 28, 2026, with full exercise of the 45-day over-allotment option.
- Issued 1,650,716 common shares, 1,312,247 pre-funded warrants and 3,407,404 warrants exercisable at $1.35 per share, expiring on the fifth anniversary of issuance.
- Net proceeds expected to be about $3.5 million after a 7.5% underwriting fee, a 1% expense allowance and other offering expenses.
- Underwriter warrant for up to 5% of securities sold; the company and its officers and directors agreed to a 90-day restriction on sales, subject to limited exceptions.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.